For the quarter ending 2026-03-31, CNTX had -$11,466,632 decrease in cash & cash equivalents over the period. -$11,466,632 in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Operating expenses-CTIM76 | 2,284,033 | - | 4,167,318 | - |
| Operating expenses-CT95 | 1,389,773 | - | 3,491,014 | - |
| Operating expenses-CT202 | 1,904,761 | - | 8,930,266 | - |
| Personnel-related costs | 2,203,587 | - | 5,414,250 | - |
| Professional fees | 689,431 | - | 1,642,602 | - |
| Share-based compensation | 409,220 | - | 1,005,912 | - |
| Other segment items | 462,994 | - | 1,246,623 | - |
| Loss from operations | -9,343,799 | - | -10,610,480 | - |
| Interest income | 520,139 | - | 833,772 | - |
| Other income (expense) | 143,088 | - | 83,471 | - |
| Net loss | -8,680,572 | -13,025,607 | -9,693,237 | -13,404,771 |
| Acquired in-process research and development charge | - | - | 0 | - |
| Research and development expense, acquired in process | - | 2,000,000 | - | - |
| Share-based compensation expense | 409,220 | 325,168 | 323,081 | 682,831 |
| Depreciation and amortization expense | 4,687 | 4,065 | 4,066 | 8,120 |
| Reduction in the carrying amount of operating lease right-of-use asset | 31,418 | 28,212 | 27,457 | 52,737 |
| Prepaid expenses and other current assets | 1,629,746 | 237,840 | -1,310,554 | -34,972 |
| Accounts payable | -67,158 | -187,989 | 324,996 | 958,960 |
| Accrued expenses and other current liabilities | -1,466,525 | 2,179,172 | 1,151,338 | 855,651 |
| Operating lease liability | -30,698 | -28,136 | -27,119 | -52,061 |
| Cash used in operating activities | -11,429,374 | -8,942,955 | -6,578,864 | -10,863,561 |
| Acquired in-process research and development | - | 2,000,000 | 0 | - |
| Purchase of property and equipment | 37,258 | 0 | 0 | 33,948 |
| Cash used in investing activities | -37,258 | -2,000,000 | 0 | -33,948 |
| Proceeds from the sale of common stock and prefunded warrants in private placement, net of offering costs | - | 0 | - | - |
| Payment of offering costs from the sale of common stock from atm facility | 0 | 0 | 0 | 15,268 |
| Cash used in financing activities | 0 | 0 | 0 | -15,268 |
| Net decrease in cash and cash equivalents | -11,466,632 | -10,942,955 | -6,578,864 | -10,912,777 |
| Cash and cash equivalents at beginning of period | 65,995,228 | 76,938,183 | 94,429,824 | - |
| Cash and cash equivalents at end of period | 54,528,596 | 65,995,228 | 76,938,183 | - |
Context Therapeutics Inc. (CNTX)
Context Therapeutics Inc. (CNTX)